Hong Kong-based biotechnology company Insilico Medicine, in a statement, announced that the Phase II trial on oral dosage of INS018_055 is currently being conducted for over 12 weeks in China, and will later be expanded to test 60 people in the US and China.
COPD is a serious disorder which makes it difficult for a person to breathe. It is one of the major causes of mortality around the world and estimates indicate that the deaths due to this condition are likely to increase by more than 30% in the next 10 years.
Dr Rana J Singh, Deputy Regional Director, South East Asia, International Union against Tuberculosis and Lung Disease (a voluntary scientific…
